Canadian Cancer Trials Group Bulletins

General


Recent Publications

Canadian Cancer Trials Group MA.5 -- Intensive CEF Versus Standard CMF as Adjuvant Therapy for Breast Carcinoma in Premenopausal Patients with Histologically Involved Axillary Nodes

Pritchard K, Munro A, O'Malley FP, Tu D, Li X, Levine M, Shepherd L, Chia S, Bartlett J. Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the Canadian Cancer Trials Group (Canadian Cancer Trials Group) MA.5 Trial (ONLINE). Breast Cancer Res Treat, 2011.

http://www.springerlink.com/content/ru50wxu8078qw432/

_____________________________________________________

Canadian Cancer Trials Group MA.17 -- Phase III Randomized Double Blind Study of Letrozole versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen

Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the Canadian Cancer Trials Group MA.17 Trial: Analyses Adjusting for Treatment Crossover (ONLINE). J Clin Oncol 2011.

http://jco.ascopubs.org/content/early/2011/10/31/JCO.2010.34.4010.abstract

_____________________________________________________


Methodological Publications

Goffin J, Pond G, Tu D. A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials. BMC Medical Research Methodology 11: 95, 2011.

http://www.biomedcentral.com/1471-2288/11/95


Li X, Chen J, Wu Y, Tu D. Constructing Nonparametric Likelihood Confidence Regions With High Order Precisions. Statistica Sinica 21: 1767-83, 2011.

http://www3.stat.sinica.edu.tw/statistica/J21N4/J21N413/J21N413.html

_____________________________________________________


General

Kay A, Higgins J, Day AG, Meyer RM, Booth CM. Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points (ONLINE). Ann Oncol 2011.

http://annonc.oxfordjournals.org/content/early/2011/11/01/annonc.mdr492.abstract